AI Proteins and Astellas sign miniprotein therapeutics deal

AI Proteins and Astellas Innovation Management have signed a research collaboration and licence deal to discover and develop miniprotein therapeutics. AI Proteins is to receive an upfront sum to design and optimise de novo miniproteins selected by Astellas. To generate the candidates, AI Proteins will deploy its computational discovery platform to design proteins targeting multiple pathways. Credit: Gorodenkoff / Shutterstock.com. AI Proteins has signed a research collaboration and licence agreement with Astellas Pharma’s affiliate Astellas Innovation Management for discovering and developing miniprotein therapeutics. Under the deal, AI Proteins is set to receive an upfront cash sum of more than $400m…

Source: Pharmaceutical Technology